TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Taro Pharmaceutical Industries Ltd (NYSE: TARO) Investor Securities Class Action Lawsuit 10/25/2016

  • If you purchased shares of Taro Pharmaceutical Industries Ltd (NYSE: TARO), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Taro Pharmaceutical Industries Ltd.
Security
NYSE: TARO

Case Name
Taro Pharmaceutical Industries Shareholder Class Action Lawsuit 10/25/2016
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Southern District of New York

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Taro Pharmaceutical Industries Ltd. .
Summary

September 24, 2018 - The court granted in part and denied in part the defendants' motion to dismiss.

October 11, 2017 - A motion to dismiss the corrected amended complaint was filed.

June 19, 2017 - A corrected amended complaint was filed.

May 22, 2017 - An amended complaint was filed.

October 25, 2016 - An investor in shares of Taro Pharmaceutical Industries Ltd (NYSE: TARO) filed a lawsuit in the U.S. District Court for the Southern District for New York over alleged violations of Federal Securities Laws by Taro Pharmaceutical Industries Ltd in connection with certain allegedly false and misleading statements made between July 3, 2014 and September 9, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Taro Pharmaceutical Industries Ltd (NYSE: TARO) common shares between July 3, 2014 and September 9, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 3, 2014 and September 9, 2016 the defendants made false and/or misleading statements and/or failed to disclose that since 2014 Taro Pharmaceutical Industries Ltd has colluded with other pharmaceutical companies to keep the price of generic products artificially high, that the foregoing conduct violated federal antitrust laws, that in turn, Taro Pharmaceutical Industries Ltd's revenues during the Class Period were the result of illegal conduct, and that as a result, Taro Pharmaceutical Industries Ltd's public statements were materially false and misleading at all relevant times.

Taro Pharmaceutical Industries Ltd reported that its Total Revenue rose from $862.94 million for the 12 months period that ended on March 31, 2015 to $950.75 million for the 12 months period that ended on March 31, 2016 and that its Net Income for those time periods increased from $484.26 million to $540.93 million.

On September 9, 2016, Taro Pharmaceutical Industries Ltd disclosed it and two of its senior officers received grand jury subpoenas in connection with a federal antitrust investigation into generic drug pricing.

Shares of Taro Pharmaceutical Industries Ltd (NYSE: TARO) declined from $145.20 per share in August 2016 to as low as $101.02 per share on October 20, 2016.